All In Biotech

Drug Trial Radar · NCT00987636

Study in Localized and Disseminated Ewing Sarcoma

Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma

Last checked: Nov 20, 2026Latest source record: Oct 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 907 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

907

Actual

Start

Oct 1, 2009

Primary completion

Mar 31, 2019

Study completion Mar 31, 2019

Sponsor

Lead sponsor
University Hospital MuensterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 48 months, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ewing Sarcoma Primary objectives: Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume \<200 mL compared to no add-on treatment. \*High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm). Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease. \*R2 accrual discontinued on December 1st 2015.

Conditions

  • Ewing's Sarcoma

Interventions

  • Zoledronic acidDrug

    intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months. Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h. Patients \>= 18 years will receive a bodyweight-dependent dose: Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h

  • BusulfanDrug

    intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW

  • TreosulfanDrug

    12 g/m² d-5 to d-3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survivalTime frame: 9.5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Hopital Essen, Pediatrics III, Hematology/ Oncology, Sarcoma Centre, International Ewing Sarcoma Study Group, West German Cancer Centre

    Essen, Germany

  • University Children´s Hospital, Pediatric Hematology and Oncology

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.